Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation

Table 3 Group3: Demonstration of demographic characteristics, structural and functional changes of group3 to which only WJ-MSC was applied

Patient no	Eye	Toxin	BCVA		Visual field FPDI		GCC thickness		VEP P100 lat		VEP P100 ampl
Patient no	Eye	Toxin	Before	After	Before	After	Before	After	Before	After	Before	After
1	R	Methanol	65	85	61	78	89	76	141	121	2.9	4.8
2	L	Methanol	60	80	56	68	82	73	145	123	2.7	3.8
3	R	Sildenafil	35	60	28	36	68	59	151	129	1.4	2.6
4	L	Sildenafil	40	70	32	37	72	63	146	119	1.8	2.9
5	R	Methanol	35	40	7	12	68	56	159	153	1.5	3.1
6	L	Methanol	35	45	10	15	71	58	152	152	1.6	6.5
7	R	Methanol	35	35	14	18	66	57	153	151	1.2	2.7
8	L	Methanol	45	60	21	27	69	59	149	141	1.7	3.2
9	R	Methanol	50	65	31	39	81	70	144	131	2.1	3.6
10	L	Methanol	54	70	33	41	86	75	140	121	2.6	3.9
11	R	Methanol	65	80	41	52	98	81	138	119	3.1	4.9
12	L	Methanol	60	74	39	49	94	80	140	121	2.9	4.6

WJ-MSC Wharton’s jelly derived mesenchymal stem cell, BCVA best corrected visual acuity (ETDRS letters), FPDI fundus perimetry deviation index (%), GCC thickness Ganglion cell complex (µm), VEP Visual evoked potential, P100 lat latency (ms), P100 ampl amplitude (mV)

ISSN: 1757-6512